drugset
drugset / Trial / NCT03666923

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923 ↗

Phase 1 Completed 12 enrolled ThromboGenics
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.

Timeline

Start
2018-09-17
Primary completion
2019-11-20
Completion
2019-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject THR-687 Unknown — Intravitreal

Indications

diabetes mellitus diabetic macular edema